THE ROLE OF CYCLOSPORINE IN THE TOPICAL TREATMENT OF DRY EYE SYNDROME: A COMPREHENSIVE REVIEW
Abstract
Dry eye disease (DED) is a multifactorial ocular surface disorder marked by instability of the tear film and inflammatory responses. This review examines the mechanisms of action, clinical effectiveness, and formulation developments of cyclosporine A (CsA). Current evidence shows CsA reduces inflammation, improves tear production, and alleviates symptoms by targeting immunopathological processes. The therapeutic outcome is influenced by the underlying cause of the disease and the specific attributes of the formulation used.
References
Golden MI, Meyer JJ, Patel BC. Dry Eye Syndrome. StatPearls. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. PMID: 28613659.
Wolffsohn JS, Arita R, Chalmers R, et al. TFOS DEWS II Diagnostic Methodology report. Ocul Surf. 2017;15(3):539-574. doi:10.1016/j.jtos.2017.05.001
Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int. 2015;112(5):71-82. doi:10.3238/arztebl.2015.0071
Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017;15(3):276-283. doi:10.1016/j.jtos.2017.05.008
Perry HD, Donnenfeld ED. Topical 0.05% cyclosporin in the treatment of dry eye. Expert Opin Pharmacother. 2004;5(10):2099-2107. doi:10.1517/14656566.5.10.2099
Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, Bosch X. Topical cyclosporine for the treatment of ocular involvement in Sjögren syndrome. Expert Rev Clin Immunol. 2012;8(1):47-53. doi:10.1586/eci.11.81
Donnenfeld ED, Solomon R, Roberts CW, et al. Cyclosporine 0.05% to improve visual outcomes after multifocal intraocular lens implantation. J Cataract Refract Surg. 2010;36(7):1095-1100. doi:10.1016/j.jcrs.2010.01.016
Pflugfelder SC, Stern ME. Biological therapy for dry eye disease: where are we?. Expert Opin Biol Ther. 2014;14(9):1277-1285. doi:10.1517/14712598.2014.922534
Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 2000;107(4):631-639. doi:10.1016/s0161-6420(99)00176-1
Barber LD, Pflugfelder SC, Tauber J, Foulks GN. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology. 2005;112(10):1790-1794. doi:10.1016/j.ophtha.2005.05.013
Views:
69
Downloads:
16
Copyright (c) 2025 Maja Ćwiek
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
